FDA Approves the First Anti-VEGF Port Delivery System for Diabetic Macular Edema
Got a patient with DME? Say goodbye to the monthly jab—Susvimo, the first continuous drug delivery system for DME just…
Exegenesis Bio Provides Updates on nAMD Gene Therapies
The race for an effective alternative to anti-VEGF therapies in nAMD heats up. Exegenesis Bio (Philadelphia, USA), a clinical-stage global…
latest posts
